Key result
Pravastatin attenuated the deterioration of renal function compared to placebo, with serum creatinine remaining stable at 1.3 mg/dl versus increasing from 1.6 to 2.1 mg/dl (p=0.05).
Why the study?
Does pravastatin improve renal function and lipid metabolism in hypertensive patients with mild renal dysfunction and hyperlipidemia?
RCT (n=57)
randomly assigned
Does pravastatin improve renal function and lipid metabolism in hypertensive patients with mild renal dysfunction and hyperlipidemia?
p-value: p=0.05
Pravastatin attenuates the deterioration of renal function and improves lipid metabolism in hypertensive patients with mild renal dysfunction and hyperlipidemia.
May support renal preservation in hypertension; leaves open confirmation in randomized trials.
The effect of pravastatin on renal function in hypertensive patients with mild renal dysfunction and hyperlipidemia was examined. A total of 57 subjects given dihydropyridine calcium blockers were randomly assigned to placebo (n = 25) and pravastatin groups (n = 32). The period of study was 6 months. In the placebo group, lipid metabolism did not change throughout the study period, but the serum creatinine concentration (Scr) increased from a baseline of 1.6+/-0.07 mg/dl to 2.1+/-0.2 mg/dl in the 6th month of study and blood urea nitrogen (BUN) increased from 26.2+/-1.1 mg/dl to 32.4+/-30.1 mg/dl. In the pravastatin group, the serum total cholesterol decreased from a baseline of 251.4+/-7.3 mg/dl to 218.2+/-6.5 mg/dl in the 6th month of study, while Scr (1.3+/-0.07 mg/dl vs. 1.3 +/-0.09 mg/dl) and BNU (20.5+/-1.2 mg/dl vs. 21.0+/-1.4 mg/dl) did not change. The change in Scr in the placebo group was significantly different from that in the pravastatin group (F = 3.75, p = 0.05). The slope of the change in 1/Scr was 0.02+/-0.07 dl x mg(-1) x month(-1) in placebo group and -0.01+/-0.03 dl x mg(-1) month(-1) in pravastatin group (P<0.05). The results indicate that pravastatin attenuates the deterioration of renal function in patients with mild renal dysfunction, together with an improvement of lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Imai et al. (1999) conducted an RCT in hypertension with mild renal dysfunction and hyperlipidemia (n=57). Pravastatin vs. Placebo was evaluated on Change in serum creatinine concentration (Scr) (p=0.05). Pravastatin attenuated the deterioration of renal function compared to placebo, with serum creatinine remaining stable at 1.3 mg/dl versus increasing from 1.6 to 2.1 mg/dl (p=0.05).